Nothing Special   »   [go: up one dir, main page]

MX2020010741A - Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer. - Google Patents

Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.

Info

Publication number
MX2020010741A
MX2020010741A MX2020010741A MX2020010741A MX2020010741A MX 2020010741 A MX2020010741 A MX 2020010741A MX 2020010741 A MX2020010741 A MX 2020010741A MX 2020010741 A MX2020010741 A MX 2020010741A MX 2020010741 A MX2020010741 A MX 2020010741A
Authority
MX
Mexico
Prior art keywords
phospholipid
methods
flavagline
same
cancer therapy
Prior art date
Application number
MX2020010741A
Other languages
English (en)
Inventor
Jarrod Longcor
Original Assignee
Cellectar Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Biosciences Inc filed Critical Cellectar Biosciences Inc
Publication of MX2020010741A publication Critical patent/MX2020010741A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se divulgan en la presente moléculas de éter de fosfolípido (PLE); además se proporcionan conjugados de fosfolípido-flavaglina ; el conjugado de fosfolípido-flavaglina puede incluir un PLE conjugado a una flavaglina a través de un enlazador; se proporcionan además en la presente métodos para tratar cáncer en un sujeto y métodos para dirigir un fármaco a un tumor o una célula de cáncer en un sujeto.
MX2020010741A 2018-04-10 2019-04-10 Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer. MX2020010741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655659P 2018-04-10 2018-04-10
PCT/US2019/026853 WO2019200017A1 (en) 2018-04-10 2019-04-10 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Publications (1)

Publication Number Publication Date
MX2020010741A true MX2020010741A (es) 2020-11-09

Family

ID=68164618

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010741A MX2020010741A (es) 2018-04-10 2019-04-10 Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.

Country Status (14)

Country Link
US (1) US20210163513A1 (es)
EP (1) EP3773544A4 (es)
JP (1) JP7402172B2 (es)
KR (1) KR20200140835A (es)
CN (1) CN112272556B (es)
AU (2) AU2019251483B2 (es)
BR (1) BR112020020759A2 (es)
CA (1) CA3095515A1 (es)
EA (1) EA202092369A1 (es)
IL (2) IL277875A (es)
MA (1) MA52247A (es)
MX (1) MX2020010741A (es)
SG (1) SG11202009549YA (es)
WO (1) WO2019200017A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017006382A (es) 2014-11-17 2018-04-10 Cellectar Biosciences Inc Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer.
MX2022003044A (es) * 2019-09-12 2022-06-02 Cellectar Biosciences Inc Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
US8022235B2 (en) * 2007-06-01 2011-09-20 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
CN103944903B (zh) 2014-04-23 2017-02-15 福建联迪商用设备有限公司 一种多方授权的apk签名方法及系统
MX2017006382A (es) 2014-11-17 2018-04-10 Cellectar Biosciences Inc Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer.
WO2017214024A1 (en) * 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
US11467159B2 (en) * 2016-06-14 2022-10-11 Cellectar Biosciences, Inc. Luminescent phospholipid analogs for the identification and isolation of circulating tumor cells
MX2022003044A (es) * 2019-09-12 2022-06-02 Cellectar Biosciences Inc Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.

Also Published As

Publication number Publication date
AU2019251483A1 (en) 2020-10-15
JP7402172B2 (ja) 2023-12-20
JP2021521169A (ja) 2021-08-26
CN112272556B (zh) 2023-12-19
CN112272556A (zh) 2021-01-26
EA202092369A1 (ru) 2021-01-26
CA3095515A1 (en) 2019-10-17
US20210163513A1 (en) 2021-06-03
SG11202009549YA (en) 2020-10-29
EP3773544A1 (en) 2021-02-17
EP3773544A4 (en) 2022-04-13
MA52247A (fr) 2021-02-17
IL304245A (en) 2023-09-01
IL277875A (en) 2020-11-30
AU2019251483B2 (en) 2021-08-05
KR20200140835A (ko) 2020-12-16
AU2021261949A1 (en) 2021-12-02
BR112020020759A2 (pt) 2021-01-19
WO2019200017A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
JOP20210073A1 (ar) مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
CY1122855T1 (el) Θεραπευτικα συστατικα δεσμευσης κυτταρικης επιφανειας με αματοξινη για τη θεραπεια ογκου
MX2023001685A (es) Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anti-cdh6.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2021015887A (es) Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
MX2019008059A (es) Anticuerpo anti-gpr20 y conjugado de anticuerpo-medicamento anti-gpr20.
PH12017500023A1 (en) Targeted conjugates and particles and formulations thereof
MX2020012997A (es) Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
EP3606964A4 (en) SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
MX2023013592A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
MX2019004963A (es) Conjugados y particulas especificos del sstr y formulaciones de los mismos.
MX2015011583A (es) Derivados de amatoxina.
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
MX2024000612A (es) Inmunoconjugados y metodos.
WO2017210246A3 (en) Penicillamine conjugates and particles and formulations thereof
JOP20210045A1 (ar) مترافقات جسم مضاد وعقار هربوكسيديين وطرق استخدامها
PH12016501185A1 (en) Compounds to fibrolast growth factor receptor-3 (fgfr3) and therapeutic uses
MX2020010741A (es) Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.
PH12020551715A1 (en) Methods of treating cancer
MX2022004341A (es) Conjugados de fosfolípido-flavaglina y métodos para usar los mismos para la terapia dirigida al cáncer.
MX2022003044A (es) Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
EP4365289A3 (en) Rna interference delivery formulation and methods for malignant tumors